Computational Methods in Road towards Drug Discovery against SARS-CoV2
暂无分享,去创建一个
[1] P. Ehrlich. Über den jetzigen Stand der Chemotherapie , 1909 .
[2] P. Gund. Three-Dimensional Pharmacophoric Pattern Searching , 1977 .
[3] R. Rhoads,et al. Progress in Molecular and Subcellular Biology , 1990, Progress in Molecular and Subcellular Biology.
[4] K. Robison,et al. A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.
[5] M. Buchmeier,et al. Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.
[6] Arthur S Slutsky,et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.
[7] D. X. Liu,et al. Coronavirus envelope protein: A small membrane protein with multiple functions , 2007, Cellular and Molecular Life Sciences.
[8] Alexander Tropsha,et al. Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.
[9] Sheng-Yong Yang,et al. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.
[10] C. Machamer,et al. The Hydrophobic Domain of Infectious Bronchitis Virus E Protein Alters the Host Secretory Pathway and Is Important for Release of Infectious Virus , 2010, Journal of Virology.
[11] J. Schwartz,et al. Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor. , 2011, ACS medicinal chemistry letters.
[12] I. Wilson,et al. A structural analysis of M protein in coronavirus assembly and morphology , 2010, Journal of Structural Biology.
[13] K. Jacobson,et al. New Insights for Drug Design from the X-Ray Crystallographic Structures of G-Protein-Coupled Receptors , 2012, Molecular Pharmacology.
[14] B. Fielding,et al. The Coronavirus Nucleocapsid Is a Multifunctional Protein , 2014, Viruses.
[15] Haitao Yang,et al. Recent progress in the discovery of inhibitors targeting coronavirus proteases , 2016, Virologica Sinica.
[16] Leonardo L. G. Ferreira,et al. Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.
[17] Tao Wang,et al. Advances in Computational Structure-Based Drug Design and Application in Drug Discovery. , 2015, Current topics in medicinal chemistry.
[18] S. Marshall,et al. Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.
[19] Sun Choi,et al. Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. , 2017, Current medicinal chemistry.
[20] Thomas Seidel,et al. 3D Pharmacophore Modeling Techniques in Computer‐Aided Molecular Design Using LigandScout , 2017 .
[21] John B. O. Mitchell,et al. Rational drug design of antineoplastic agents using 3D-QSAR, cheminformatic, and virtual screening approaches. , 2019, Current medicinal chemistry.
[22] J. Ziller,et al. X-ray crystallographic structure of a teixobactin analogue reveals key interactions of the teixobactin pharmacophore. , 2017, Chemical communications.
[23] T. Fung,et al. Post-translational modifications of coronavirus proteins: roles and function , 2018, Future virology.
[24] S. Perlman,et al. Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and Pathogenesis , 2018, mBio.
[25] R. Kist,et al. Searching for potential mTOR inhibitors: Ligand-based drug design, docking and molecular dynamics studies of rapamycin binding site. , 2017, Journal of molecular graphics & modelling.
[26] Gaoqi He,et al. An Improved Receptor-Based Pharmacophore Generation Algorithm Guided by Atomic Chemical Characteristics and Hybridization Types , 2018, Front. Pharmacol..
[27] M. Heller,et al. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling , 2018, eLife.
[28] K. Sankaranarayanan,et al. Identification of potential CRAC channel inhibitors: Pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach , 2019, SAR and QSAR in environmental research.
[29] Entedar A J Alsaadi,et al. Membrane binding proteins of coronaviruses , 2019, Future virology.
[30] K. To,et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.
[31] Lisa E. Gralinski,et al. Return of the Coronavirus: 2019-nCoV , 2020, Viruses.
[32] A. Godzik,et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, bioRxiv.
[33] Bhumi M. Shah,et al. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.
[34] U. Jha,et al. A review of the 2019 novel coronavirus (COVID-19) based on current evidence , 2020 .
[35] Sumra Wajid Abbasi,et al. Stilbene-based natural compounds as promising drug candidates against COVID-19 , 2020, Journal of biomolecular structure & dynamics.
[36] Junmei Wang,et al. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study , 2020, Journal of chemical information and modeling.
[37] Suresh Kumar. Drug and Vaccine Design against Novel Coronavirus (2019-nCoV) Spike Protein through Computational Approach , 2020 .
[38] Sairaj Satarker,et al. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2 , 2020, Archives of Medical Research.
[39] Xiaoqian Lin,et al. A Review on Applications of Computational Methods in Drug Screening and Design , 2020, Molecules.
[40] Lixia Chen,et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.
[41] Jane Parr. Pneumonia in China: lack of information raises concerns among Hong Kong health workers. , 2020, BMJ.
[42] B. Medhi,et al. Drug targets for corona virus: A systematic review , 2020, Indian journal of pharmacology.
[43] Sk Abdul Amin,et al. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors , 2020, Journal of biomolecular structure & dynamics.
[44] G. Gao,et al. A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020 , 2020, China CDC weekly.
[45] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[46] Jiachen Sun,et al. A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019‐nCoV) , 2020, Journal of medical virology.
[47] Binding site analysis of potential protease inhibitors of COVID-19 using AutoDock , 2020, VirusDisease.
[48] M. Roser,et al. Coronavirus Pandemic (COVID-19) , 2020 .
[49] Crystal structure of Nsp15 endoribonuclease NendoU from SARS‐CoV‐2 , 2020, Protein science : a publication of the Protein Society.
[50] L. Guddat,et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus , 2020, Science.
[51] R. Hilgenfeld,et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.